PlumX Metrics
Embed PlumX Metrics

Coenzyme Q and statin myalgia: What is the evidence?

Current Atherosclerosis Reports, ISSN: 1523-3804, Vol: 12, Issue: 6, Page: 407-413
2010
  • 39
    Citations
  • 0
    Usage
  • 49
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Statins lower cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the biosynthesis of cholesterol. However, severe adverse events, including myalgias and rhabdomyolysis, have been reported with statin treatment. Different mechanisms have been proposed to explain statin-induced myopathy, including reduction of mevalonate pathway products, induction of apoptosis, mitochondrial dysfunction, and genetic predisposition. A decrease in coenzyme Q (CoQ), a product of the mevalonate pathway, could contribute to statin induced myopathy. This article reviews the clinical and biochemical features of statin-induced myopathy, the inter-relationship between statins and the concentration of CoQ in plasma and tissues, and whether there is a role for supplementation with CoQ to attenuate statin-induced myopathy. © 2010 Springer Science+Business Media, LLC.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know